Related Experiment Video
Updated: Aug 10, 2026

Iris Fixation via External Pentagram Suturing
Published on: May 5, 2022
The Ahmed drainage implant in the treatment of pediatric glaucoma
Yair Morad1, Craig E Donaldson, Yuri M Kim
1Department of Ophthalmology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Insights
Ahmed Glaucoma Valve implantation effectively manages pediatric glaucoma, reducing intraocular pressure and medication needs. However, close monitoring is crucial due to a high rate of complications.
Area of Science:
- Ophthalmology
- Glaucoma Management
- Pediatric Surgery
Background:
- Pediatric glaucoma presents unique management challenges.
- Intraocular pressure (IOP) control is critical to prevent vision loss.
- The Ahmed Glaucoma Valve is a device used to manage refractory glaucoma.
Purpose of the Study:
- To evaluate the safety and efficacy of Ahmed Glaucoma Valve implantation in pediatric glaucoma patients.
- To assess early and intermediate outcomes, including IOP control and medication requirements.
- To identify complications associated with the procedure.
Main Methods:
- A retrospective case series of 60 eyes from 44 pediatric glaucoma patients.
- Ahmed Glaucoma Valve implantation was performed for medically uncontrolled IOP.
- Outcomes included IOP below 21 mm Hg, need for medications, and visual acuity changes.
Main Results:
- Successful IOP control was achieved in 73% of eyes at an average follow-up of 24.3 months.
- Postoperative IOP significantly decreased (32.8 to 16.6 mm Hg, P <.0001).
- Complications occurred in 50% of eyes, with uveitis being a risk factor for tube exposure.
Conclusions:
- Ahmed Glaucoma Valve implantation is an effective treatment for pediatric glaucoma.
- Antiglaucoma medications are often still required post-surgery.
- A high incidence of complications necessitates vigilant postoperative follow-up.
Purpose:
To report the safety and efficacy of Ahmed Glaucoma Valve (New World Medical, Inc., Rancho Cucamonga, California, USA) implantation for the management of pediatric glaucoma in the early and intermediate follow-up period.
Design:
Consecutive interventional case series.
Method:
A retrospective chart review was conducted on 60 eyes (44 patients, age range at surgery 1.5 months to 16 years, average 6 +/- 4.9 years), with pediatric glaucoma that underwent Ahmed Glaucoma Valve implantation for medically uncontrolled intraocular pressure (IOP) between the years 1995 and 2000. Outcome measures were control of IOP below 21 mm Hg, the need for antiglaucoma medications after surgery, and loss of 2 or more lines of Snellen acuity. Complications were monitored.
Results:
The postoperative follow-up period for each eye averaged 24.3 +/- 16 months (range, 3 to 60 months). At last follow-up, IOP was controlled in 44 eyes (73%), 11 of which did not need antiglaucoma therapy. Kaplan-Meier life-table analysis showed probability of success with or without medications of 93% (95% confidence interval [CI], 86%-100%), 86% (95% CI, 77%-96%), 71% (95% CI, 59%-87%), and 45% (95% CI, 28%-80%) after 12, 24, 36, and 48 months of follow-up. Average IOP decreased from 32.8 +/- 6.2 before surgery to 16.6 +/- 8.0 postoperatively (P <.0001). The average number of medications used decreased from 4.4 +/- 1.97 to 2.0 +/- 2.0 (P <.0001). Kaplan-Meier survival analysis did not reveal any difference in survival profiles related to specific diagnosis of glaucoma, age (above or below 18 months), or prior surgery. Complications occurred in 30 eyes (50%). Although most resolved or were treated successfully, four patients had severe visual loss during the follow-up. Uveitis was a significant risk factor for tube exposure (Fisher exact test, P =.006).
Conclusions:
Ahmed Glaucoma Valve implantation is an effective treatment for pediatric glaucoma, although patients frequently require antiglaucoma medications. However, a high rate of potentially sight-threatening postoperative complications warrants ongoing close follow-up.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Ophthalmic Drug Delivery Systems

